Average changes of the body weight of karpas299 lymphoma-bearing SCID/NOD wild-type and SCID/NOD FcRγ^–/– mice during the course of the treatment. (A) SCID/NOD wild-type mice (n = 15). (B) SCID/NOD FcRγ^–/– mice (n = 10-12). The body weight of both SCID/NOD wild-type and SCID/NOD FcRγ^–/– mice bearing karpas299 lymphoma in the control groups decreased rapidly after 2 weeks from the start of the experiment. HeFi-1 treatment delayed the decrease of the body weight of both SCID/NOD wild-type and SCID/NOD FcRγ^–/– mice. The daclizumab treatment slowed down the decrease of body weight of SCID/NOD wild-type mice but did not show this effect in SCID/NOD FcRγ^–/– mice. *P < .05, **P < .01.